ClinicalTrials.gg
RecruitingNCT07477054AERO-PASUpdated Oct 30, 2026

A Post-Approval Multicenter Study to Assess the Continued Safety and Effectiveness of the AeroPace® System

An interventional study of Lungpacer Diaphragm Pacing Therapy in Ventilator Induced Diaphragm Dysfunction, sponsored by Lungpacer Medical Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Lungpacer Medical Inc. · Not applicable, Interventional, and Treatment

How we know

Updated Oct 30, 2026Now RecruitingFirst site in United States+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

A single-arm, prospective, multicenter cohort study to assess the 30-day continued safety and effectiveness of the AeroPace System in patients on mechanical ventilation (MV) at least 96 hours and who have not weaned. This is a study collecting real-world data in a post-market setting.

02

Conditions studied

  • Ventilator Induced Diaphragm Dysfunction

Keywords

  • VIDD
  • Diaphragm Atrophy
  • Weaning Failure
  • SBT
  • Phrenic Nerve Stimulation
03

In context

Lead sponsor

Lungpacer Medical Inc. is the lead sponsor of 8 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Are 18 years or older, and,
  2. Will have been mechanically ventilated for ≥96 hours (4 days) by the time of Catheter insertion, and,
  3. Have not weaned from MV, and,
  4. Have failed an institutional SBT within 48 hours of enrollment.

Exclusion criteria

Exclusion Criteria:

  1. Invasive mechanical ventilation >90 days.
  2. Currently on extracorporeal membrane oxygenation (ECMO).
  3. Weaning failure due to hypervolemia.
  4. Medical history (including imaging) or known anatomy that prevents percutaneous insertion of the Catheter into the intended thoracic vein on the left side.
  5. Clinically overt congestive heart failure that is preventing weaning.
  6. Currently being treated with neuromuscular blockade that could affect phrenic nerve / diaphragm contraction.
  7. Pre-existing neurological, neuromuscular or muscular disorder that could affect the respiratory muscles.
  8. Pre-existing severe chronic pulmonary fibrosis.
  9. Known pleural effusions occupying greater than one third of the pleural space on either side.
  10. >70 kg/m2.
  11. Known or suspected phrenic nerve paralysis.
  12. Any electrical device (implanted or external) that may be prone to interaction with, or interference from the AeroPace System, including neurological pacing/stimulator devices, cardiac pacemakers and defibrillators.
  13. Current hemodynamic instability
  14. Uncontrolled sepsis or septic shock.
  15. Current or untreated bacteremia.
  16. Expecting withdrawal of life support and/or shift to palliation as the goal of care.
  17. Known or suspected to be pregnant or lactating.
  18. Currently being treated in another clinical trial studying an experimental treatment that could affect the study primary outcome.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Other
    Lungpacer AeroPace Therapy

    Subject receives AeroPace therapy consisting of 60 stimulations, twice daily for a total of 120 stimulations/day, plus standard of care for weaning from mechanical ventilation including at least once daily spontaneous breathing trials.

    Device: Lungpacer Diaphragm Pacing Therapy

Interventions

  • DeviceLungpacer Diaphragm Pacing Therapy

    Transvenous phrenic nerve stimulation to induce diaphragm contraction.

    Also known as: Lungpacer DPTS, AeroPace System

06

What researchers measure

Primary outcomes

  1. Adverse Event Profile

    All Serious Adverse Events from enrollment to study exit and device- and/or procedure-related Adverse Events until successful wean, withdrawal/death, transfer or day 30 (whichever comes first).

    Time frame: 30 days

  2. Successful Weaning

    Proportion of subjects successfully weaned by Day 30

    Time frame: 30 days

Secondary outcomes

  1. Days on mechanical ventilation from time of initial placement procedure through Day 30.

    Time frame: 30 days

  2. Incidence of reintubation/reinstatement of MV through Day 30

    Time frame: 30 days

  3. Incidence of device/procedure related SAEs as compared to RESCUE 3 Treatment group subjects

    Time frame: 30 days

  4. Mortality through Day 30

    Time frame: 30 days

  5. Incidence of tracheostomy from enrollment through Day 30

    Time frame: 30 days

  6. ICU/hospital days from initial placement procedure to Day 32

    Time frame: 32 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Aug 2028, 22 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2026
First posted
Mar 17, 2026
StartEst.
Oct 31, 2026
Primary completionEst.
Aug 31, 2028
CompletionEst.
Sep 30, 2028
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 30, 2026
Sites
1 site added — first site in United States
Show site
  • Sutter Health Research Institute · San Francisco, United States
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in United States
    Show site
    • Sutter Health Research Institute · San Francisco, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07477054
Lead sponsor
Lungpacer Medical Inc.
Responsible party
Sponsor
First posted
Mar 17, 2026
Start date
Oct 31, 2026 (estimated)
Primary completion
Aug 31, 2028 (estimated)
Completion
Sep 30, 2028 (estimated)
Last update
Oct 30, 2026

Study contacts

Megan Cotts
Contact
mcotts@lungpacer.com
(612) 986-7172
AERO-PAS Study
Contact
aero-pas@lungpacer.com

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion